Breaking News Instant updates and real-time market news.

NKTR

Nektar

$101.44

-0.41 (-0.40%)

13:05
04/06/18
04/06
13:05
04/06/18
13:05

Nektar call volume above normal and directionally bullish

Bullish option flow detected in Nektar with 3,289 calls trading, 4x expected, and implied vol increasing over 5 points to 74.81%. May-18 110 calls and Apr-18 90 puts are the most active options, with total volume in those strikes near 2,800 contracts. The Put/Call Ratio is 0.43. Earnings are expected on May 9th.

  • 14

    Apr

  • 03

    May

  • 12

    Jun

NKTR Nektar
$101.44

-0.41 (-0.40%)

03/02/18
JPMS
03/02/18
NO CHANGE
Target $90
JPMS
Overweight
Nektar announced another positive update on NKTR-214, says JPMorgan
Nektar Therapeutics last night announced another positive update on NKTR-214 from the phase I dose escalation study and reported additional patients converted to responders, JPMorgan analyst Jessica Fye tells investors in a post-earnings research note. The analyst continues to see NKTR-214, along with the company's immunology/immuno-oncology pipeline, driving potential "significant value creation." She keeps an Overweight rating on Nektar with a $90 price target.
03/02/18
MZHO
03/02/18
NO CHANGE
Target $89
MZHO
Buy
Mizuho has increased conviction in Bristol possibly buying Nektar in 2018
Mizuho analyst Difei Yang believes there is a possibility for Bristol-Myers Squibb (BMY) to acquire Nektar Therapeutics (NKTR) in 2018. The analyst says new positive clinical data of NKTR-214 in combo with Bristol-Myers' Opdivo reinforces her conviction. Bristol-Myers "could make a move" prior to the readouts of Propel study, expected in the second half of 2018, where NKTR-214 was tested in combo with competing products, Tecentiq and Keytruda, Yang tells investors in a research note. The analyst keeps a Buy rating on Nektar with an $89 price target following the company's Q4 results.
03/02/18
ADAM
03/02/18
NO CHANGE
Target $94
ADAM
Buy
Nektar price target raised to $94 from $80 at Canaccord
Canaccord Genuity analyst Arlinda Lee raised her price target for Nektar Therapeutics to $94 after the company reported Q4 results. Notable, Nektar provided a second update to Phase 1 Pivot-2 dose-escalation results indicating ongoing and further tumor shrinkage with improved and continuing response, Lee tells investors in a research note. Further, the company reported 60% response rate in 20 patients with PDL1-negative tumors at baseline, the analyst adds. She believes the update "further solidifies the central positioning" for wholly-owned drug candidate NKTR-214 in combination with anti-PD1. The analyst keeps a Buy rating on Nektar.
04/02/18
HCWC
04/02/18
INITIATION
Target $125
HCWC
Buy
Nektar assumed with a Buy at H.C. Wainwright
H.C. Wainwright analyst Debjit Chattopadhyay assumed coverage of Nektar Therapeutics with a Buy rating and $125 price target. The stock has had a "stellar run, but activity in checkpoint refractory patients could be well received," Chattopadhyay tells investors in a research note. The analyst believes available data from NKTR-214 in combination with Opdivo points to "compelling clinical activity." He sees "significant upside to the stock" beyond what his $125 target suggests should the data hold up to scrutiny.

TODAY'S FREE FLY STORIES

ONDK

On Deck Capital

$8.09

0.6 (8.01%)

07:32
07/19/18
07/19
07:32
07/19/18
07:32
Downgrade
On Deck Capital rating change  »

Morgan Stanley sees On…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Aug

  • 08

    Aug

  • 15

    Aug

  • 16

    Aug

ADS

Alliance Data

$226.51

1.13 (0.50%)

07:32
07/19/18
07/19
07:32
07/19/18
07:32
Earnings
Breaking Earnings news story on Alliance Data »

Alliance Data backs FY18…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 08

    Aug

ADS

Alliance Data

$226.51

1.13 (0.50%)

07:31
07/19/18
07/19
07:31
07/19/18
07:31
Earnings
Alliance Data backs FY18 core EPS view $22.50 to $23.00, consensus $22.57 »

CEO Heffernan continued:…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 08

    Aug

DPZ

Domino's Pizza

$283.74

1.74 (0.62%)

07:31
07/19/18
07/19
07:31
07/19/18
07:31
Earnings
Domino's Pizza reports Q2 adjusted EPS $1.84, consensus $1.75 »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 21

    Sep

  • 05

    Oct

ADS

Alliance Data

$226.51

1.13 (0.50%)

07:30
07/19/18
07/19
07:30
07/19/18
07:30
Earnings
Alliance Data reports Q2 core EPS $5.01, consensus $4.66 »

Reports Q2 revenue $1.9B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 08

    Aug

LONE

Lonestar Resources

$10.37

0.42 (4.22%)

07:30
07/19/18
07/19
07:30
07/19/18
07:30
Initiation
Lonestar Resources initiated  »

Lonestar Resources…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Aug

CMCSA

Comcast

$34.03

-0.23 (-0.67%)

, FOXA

21st Century Fox

$46.69

0.22 (0.47%)

07:30
07/19/18
07/19
07:30
07/19/18
07:30
Options
Unusual put flow in option market yesterday »

Notable put activity was…

CMCSA

Comcast

$34.03

-0.23 (-0.67%)

FOXA

21st Century Fox

$46.69

0.22 (0.47%)

GM

General Motors

$39.87

-0.185 (-0.46%)

PZZA

Papa John's

$53.60

2.06 (4.00%)

HPQ

HP Inc.

$23.54

-0.06 (-0.25%)

GOGO

Gogo

$3.91

0.15 (3.99%)

MDR

McDermott

$17.97

-0.075 (-0.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 27

    Jul

  • 31

    Jul

SQ

Square

$68.30

-0.02 (-0.03%)

07:28
07/19/18
07/19
07:28
07/19/18
07:28
Upgrade
Square rating change  »

Square upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

  • 15

    Aug

  • 16

    Aug

MEET

Meet Group

$4.14

0.08 (1.97%)

07:26
07/19/18
07/19
07:26
07/19/18
07:26
Upgrade
Meet Group rating change  »

Meet Group upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMRN

Amarin

$2.86

-0.1 (-3.38%)

07:26
07/19/18
07/19
07:26
07/19/18
07:26
Recommendations
Amarin analyst commentary  »

Amarin's Vascepa…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JPM

JPMorgan

$111.52

1.01 (0.91%)

07:25
07/19/18
07/19
07:25
07/19/18
07:25
Upgrade
JPMorgan rating change  »

JPMorgan upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Oct

EBAY

eBay

$37.95

0.13 (0.34%)

07:25
07/19/18
07/19
07:25
07/19/18
07:25
Recommendations
eBay analyst commentary  »

eBay price target lowered…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FFIV

F5 Networks

$179.52

2.86 (1.62%)

07:24
07/19/18
07/19
07:24
07/19/18
07:24
Downgrade
F5 Networks rating change  »

Morgan Stanley sees risk…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 08

    Aug

CMG

Chipotle

$453.56

0.77 (0.17%)

, SBUX

Starbucks

$51.15

-0.12 (-0.23%)

07:24
07/19/18
07/19
07:24
07/19/18
07:24
Recommendations
Chipotle, Starbucks analyst commentary  »

Wedbush cautious on…

CMG

Chipotle

$453.56

0.77 (0.17%)

SBUX

Starbucks

$51.15

-0.12 (-0.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 26

    Jul

PTCT

PTC Therapeutics

$35.02

-0.19 (-0.54%)

07:23
07/19/18
07/19
07:23
07/19/18
07:23
Initiation
PTC Therapeutics initiated  »

PTC Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HRTX

Heron Therapeutics

$37.75

-0.35 (-0.92%)

07:22
07/19/18
07/19
07:22
07/19/18
07:22
Recommendations
Heron Therapeutics analyst commentary  »

Heron Therapeutics price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MTB

M&T Bank

$174.38

5.77 (3.42%)

07:20
07/19/18
07/19
07:20
07/19/18
07:20
Recommendations
M&T Bank analyst commentary  »

M&T Bank price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:20
07/19/18
07/19
07:20
07/19/18
07:20
General news
Treasury Market Outlook: Treasury yields have extended slightly higher »

Treasury Market Outlook:…

WRD

WildHorse Resource

07:19
07/19/18
07/19
07:19
07/19/18
07:19
Initiation
WildHorse Resource initiated  »

WildHorse Resource…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Aug

  • 19

    Aug

ARA

American Renal Associates

07:19
07/19/18
07/19
07:19
07/19/18
07:19
Initiation
American Renal Associates initiated  »

American Renal Associates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BIG

Big Lots

$42.76

0.39 (0.92%)

07:19
07/19/18
07/19
07:19
07/19/18
07:19
Initiation
Big Lots initiated  »

Big Lots initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:18
07/19/18
07/19
07:18
07/19/18
07:18
General news
Futures lower as trade war rhetoric, earnings reporting continues »

Stock futures are…

LITE

Lumentum

$59.30

-0.05 (-0.08%)

, VIAV

Viavi

$10.39

-0.09 (-0.86%)

07:17
07/19/18
07/19
07:17
07/19/18
07:17
Recommendations
Lumentum, Viavi, Apple analyst commentary  »

JPMorgan raises 3D…

LITE

Lumentum

$59.30

-0.05 (-0.08%)

VIAV

Viavi

$10.39

-0.09 (-0.86%)

AAPL

Apple

$190.43

-1.12 (-0.58%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

  • 14

    Aug

HNHPF

Hon Hai Precision

$0.00

(0.00%)

07:17
07/19/18
07/19
07:17
07/19/18
07:17
Periodicals
Foxconn interested in webcast business opportunities, DigiTimes reports »

Foxconn has been building…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AXP

American Express

$102.98

1.84 (1.82%)

07:15
07/19/18
07/19
07:15
07/19/18
07:15
Recommendations
American Express analyst commentary  »

American Express Q2…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Aug

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.